Press Releases

Perrigo is a leading global consumer-focused self-care company. Our vision is to make lives better by bringing “Quality, Affordable Self-Care Products” that consumers trust everywhere they are sold. The Company is a leading provider of health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.

Learn More

Perrigo Company Announces Tentative Approval for Glimepiride Tablets

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that, through a partnership with InvaGen Pharmaceuticals, it has received tentative approval from the U.S. Food and Drug Administration (FDA) to market Glimepiride Tablets, 1 mg, 2 mg and 4 mg. Final approval is anticipated upon brand patent expiration on October 6, 2005.

The product is the AB-rated equivalent to Aventis' Amaryl® Tablets, 1 mg, 2 mg and 4 mg, indicated for the treatment of diabetes.

Annual sales for the brand are approximately $350 million, according to IMS data.

The Perrigo Company is a leading global healthcare supplier and the world's largest manufacturer of over-the-counter (OTC) pharmaceutical and nutritional products for the store brand market. Store brand products are sold by food, drug, mass merchandise, dollar store and club store retailers under their own labels. The Company also develops, manufactures and markets prescription generic drugs, active pharmaceutical ingredients and consumer products, and operates manufacturing facilities in the United States, Israel, United Kingdom, Mexico and Germany. Visit Perrigo on the Internet ( ).

SOURCE: Perrigo Company

CONTACT: Ernest J. Schenk, Manager, Investor Relations and Communication
of Perrigo Company, +1-269-673-9212, or E-mail:

Web site: